Wednesday, 18 November 2026European Markets

GUERBET Stock 9.64% Up On Wednesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - the market ended the session with guerbet (gbt.pa) jumping 9.64% to €22.75 on wednesday while cac 40 slid 0.27% to €7,656.75.

guerbet's last close was €20.75, 10.56% under its 52-week high of €23.20.

about guerbet

guerbet sa engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. the company offers optiray and xenetix, which are non-ionic monomeric and iodinated contrast agents; telebrix gastro, a meglumine ioxitalamate solution; conray, an iothalamate meglumine injection; micropaque/microtrast, a diagnostic imaging interconnected solution; dotarem, a gadoteric acid-gadoterate meglumine, and artirem, a gadoteric acid that acts as a contrast agent for mri, as well as prefilled syringes, injectors, accessories, and consumables for mri, ct, and cath lab. it also provides digital solutions, such as contrast&care, an injection management solution; dose&care, an x-ray dose management solution; and icobrain, a cloud-based ai solution to quantify disease-specific brain structures for acute and chronic neurological conditions on mr and ct, as well as optiprotect services. in addition, the company provides products for interventional radiology, including lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; patent blue v, a blue dye; axessio, a peripheral micro guidewire; and sequre and drakon, which are microcatheters. further, it offers hydra vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. the company was incorporated in 1926 and is headquartered in villepinte, france.

earnings per share

as for profitability, guerbet has a trailing twelve months eps of €-3.35.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -10.79%.

more news about guerbet (gbt.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 31 Jan 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›